Statement of Research!America CEO and President Mary Woolley on Cures 2.0 Act
Research!America applauds Reps. Diana DeGette (D-CO) and Fred Upton (R-MI) for their extraordinary leadership, commitment, and vision to accelerate medical and public health progress, demonstrated once again by today’s introduction of the Cures 2.0 Act.
Medical progress – or the lack thereof – bears on the quality and length of life for every American and all peoples across the globe.
From providing $25 billion to bolster our nation’s COVID-19-weakened R&D capacity, to ensuring a greater share of grant funding goes to research rather than red tape, to joining Rep. Anna Eshoo (D-CA) in furthering the progress needed to stand up ARPA-H, the legislation would dramatically strengthen our nation’s R&D architecture.
Further, the Cures 2.0 Act would advance such crucial objectives as addressing long-COVID, bolstering pandemic preparedness, fostering clinical trial diversity, empowering early diagnosis of rare diseases, incentivizing the development of urgently needed antibiotics, and laying the foundation for joint efforts with the Administration to foster accelerated access to breakthrough medical technologies.
We thank Reps. DeGette and Upton and their dedicated staff members for leveraging so many innovative, bipartisan proposals to create a launch-pad for urgently needed medical and public health progress.
Contact Tim Haynes, Senior Director of Communications, at 571-482-2737 or thaynes@researchamerica.org with press inquiries.